Mayne Pharma, Inc. v. Murty Pharmaceuticals, Inc.
Plaintiff: Mayne Pharma, Inc.
Defendant: Murty Pharmaceuticals, Inc.
Case Number: 5:2020cv00114
Filed: March 23, 2020
Court: US District Court for the Eastern District of Kentucky
Presiding Judge: Matthew A Stinnett
Referring Judge: Robert E Wier
Nature of Suit: Contract: Other
Cause of Action: 28 U.S.C. ยง 1332
Jury Demanded By: Defendant
Docket Report

This docket was last retrieved on May 13, 2020. A more recent docket listing may be available from PACER.

Date Filed Document Text
May 13, 2020 ***FILE SUBMITTED TO CHAMBERS of Magistrate Judge Matthew A. Stinnett for review: #10 Answer to Counterclaim by Mayne Pharma, Inc. (MDC)
May 12, 2020 Filing 10 ANSWER to #5 Answer to Complaint,, Counterclaim, by Mayne Pharma, Inc..(Brooker, Christopher)
May 6, 2020 Opinion or Order Filing 9 ORDER: 1) Within 21 days from the date of service of this order, parties shall meet to discuss the nature and basis of their claims & defenses and possibilities for a settlement or resolution of the case. 2) Within 10 days after meeting parties shall file a joint status report containing: a) the discovery plan; b) parties' belief as to whether the matter is suitable for alternative dispute resolution; c) parties' estimate of time necessary to file pretrial motions; d) probably length of trial; e) dates mutually convenient for trial; and f) decision as to whether the action may be referred to a US Magistrate Judge. To the extent any party is a partnership or limited liability entity, and the parties seek jurisdiction based on 28 U.S.C. 1332, that party shall disclose to the Court each partner and/or member and their domiciles. Signed by Magistrate Judge Matthew A. Stinnett on 05/06/2020. (Attachments: #1 MJ Consent Form) (MDC) cc: COR
April 23, 2020 Opinion or Order Filing 7 STANDING CASE MANAGEMENT AND REFERRAL ORDER: 1. At the outset, the Court reminds the parties that, under Rule 1, they share with the Court the duty to construe, administer, and employ the Federal Rules of Civil Procedure to secure the just, speedy, and inexpensive determination of this action; 2. Pursuant to 28:636(b)(1) and Fed. R. Civ. P. 72, the Court refers this case to the appropriate United States Magistrate Judge for this Division; 3. Unless otherwise ordered, the Court retains for decision any motion dispositive of a claim or defense (as well as motions regulating the trial proof, including Daubert and motions in limine); 4. Concurrent with the filing of any Rule 12 motion, the moving party may file, as a separate motion, any request for a discovery stay pending resolution. The Court refers consideration of any such motion to the assigned Magistrate Judge; 5. Discovery Disputes shall be resolved as defined within this order; The Court DIRECTS the Clerk to enter this Standing Order in the undersigned's civil cases excepting Social Security, pro se, and prisoner post-conviction matters at case opening (or as the Court otherwise directs). Signed by Judge Robert E. Wier. (JJ)cc: COR
April 23, 2020 ***FILE SUBMITTED TO CHAMBERS of Judge Robert E. Wier for review: #5 Answer to Complaint,, Counterclaim, #1 Complaint, (JJ)
April 22, 2020 Filing 6 FRCP 7.1 DISCLOSURE STATEMENT by Murty Pharmaceuticals, Inc.. (Rager, Tonya)
April 22, 2020 Filing 5 ANSWER to #1 Complaint, with Jury Demand , COUNTERCLAIM against Mayne Pharma, Inc. by Murty Pharmaceuticals, Inc.. (Attachments: #1 Exhibit Exh A - Trade Terms, #2 Exhibit Exh B - GDUFA Inv, #3 Exhibit Exh C - Rev PO, #4 Exhibit Exh D - Twiddy Email, #5 Exhibit Exh E - Reported Sales, #6 Exhibit Exh F - Freight Charges)(Rager, Tonya)
March 24, 2020 Filing 4 FRCP 7.1 DISCLOSURE STATEMENT by Mayne Pharma, Inc. identifying Corporate Parent Mayne Pharma Group Limited for Mayne Pharma, Inc... (Brooker, Christopher)
March 23, 2020 Filing 3 Summons Issued as to Murty Pharmaceuticals, Inc.; Summons issued and returned to counsel electronically (MDC)
March 23, 2020 Filing 1 COMPLAINT ( Filing fee $400; receipt number 0643-4628089), filed by Mayne Pharma, Inc.. (Attachments: #1 Civil Cover Sheet, #2 Exhibit 1- Agreement, #3 Exhibit 2- Amendment 1 to Agreement, #4 Exhibit 3-12/21/15 Amendment to Agreement, #5 Exhibit 4- Notice of Non-Renewal, #6 Summons Murty Pharmaceuticals, Inc)(MDC)
March 23, 2020 Conflict Check run. (MDC)

Access additional case information on PACER

Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.

Access this case on the Kentucky Eastern District Court's Electronic Court Filings (ECF) System

Search for this case: Mayne Pharma, Inc. v. Murty Pharmaceuticals, Inc.
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Web [ Unicourt | Legal Web | Google | Bing | Yahoo | Ask ]
Plaintiff: Mayne Pharma, Inc.
Represented By: Christopher Wilson Brooker
Represented By: Sean Gregory Williamson
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Defendant: Murty Pharmaceuticals, Inc.
Represented By: Tonya S. Rager
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.


Why Is My Information Online?